Intravenous Magnesium Sulphate as an Adjuvant Therapy for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Abstract

<b>Background</b>: Intravenous magnesium sulfate (IV MgSO₄) may serve as an effective adjunct therapy to improve clinical outcomes in patients experiencing acute exacerbations of chronic obstructive pulmonary disease (AECOPDs). <b>Methods</b>: A comprehensive search was conducted on PubMed, Cochrane, and EMBASE from inception to April 2025 to find eligible studies comparing IV MgSO₄ plus standard treatment versus standard treatment alone. A random-effects meta-analysis was conducted using RevMan. <b>Results</b>: Nine studies (seven RCTs and two observational studies) met the inclusion criteria. Pooled analysis demonstrated that adjunctive IV MgSO₄ significantly improved peak expiratory flow rate at 45 min (MD = 18.50, 95% CI = 6.36 to 30.65) and significantly reduced hospital admission rates from the emergency department (OR = 0.45, 95% CI = 0.23 to 0.88). No significant differences were observed in the length of hospital stay (MD = -0.83, 95% CI = -2.99 to 1.33) and adverse events (OR = 0.79, 95% CI = 0.20 to 3.13; <i>p</i> = 0.73, I² = 25%) between the two groups. <b>Conclusions</b>: Adjunct MgSO₄ in AECOPD is associated with significant improvement in peak expiratory flow rate at 45 min and reduced hospitalization rates. Additional large-scale, multicenter randomized controlled trials are needed to validate and strengthen these findings.